On Thursday, June 27, 2024, at 8:00 am ET, we will host a virtual investor event to review new interim results from our ongoing Phase 2 clinical trial exploring the use of our lead candidate in people with chronic neutropenia. Learn more and register for the event here: https://bit.ly/3V17C6X
X4 Pharmaceuticals
Biotechnology Research
Boston, Massachusetts 10,104 followers
Enabling a better future for people with rare immune disorders
About us
We are a commercial-stage clinical biopharmaceutical company driven to improve the lives of people with rare diseases of the immune system and few to no treatment options. We have successfully developed mavorixafor, receiving FDA approval for XOLREMDI™ (mavorixafor) in its first indication, and are currently executing our US launch. We are also advancing mavorixafor for additional rare disease patient populations, and expect to initiate a pivotal, global Phase 3 clinical trial in people with certain chronic neutropenic disorders. With a focus on CXCR4 and immune system biology, we continue to leverage our expertise both at our corporate headquarters in Boston, Massachusetts and at our research center of excellence in Vienna, Austria to further advance our patient-centric mission.
- Website
-
http://www.x4pharma.com
External link for X4 Pharmaceuticals
- Industry
- Biotechnology Research
- Company size
- 51-200 employees
- Headquarters
- Boston, Massachusetts
- Type
- Public Company
- Founded
- 2014
- Specialties
- Rare disease and primary immunodeficiencies
Locations
-
Primary
Get directions
61 N Beacon St
Boston, Massachusetts 02134, US
Employees at X4 Pharmaceuticals
Updates
-
Today we announced that our management team will be participating in the upcoming H.C. Wainwright & Co., LLC 2nd Annual BioConnect Investor Conference, taking place on May 20th, 2024, at the Nasdaq Stock Exchange in New York City. Learn more here: https://bit.ly/4beRuWp
-
-
Today, we reported financial results and provided a corporate update for the first quarter 2024. Click here to learn more and to access the webcast replay: https://brnw.ch/21wJxF0
-
-
This week, X4 is participating in the Clinical Immunology Society (CIS) #CIS2024 conference, where we are connecting with attendees to share information about XOLREMDI™ (mavorixafor), which is now FDA approved. Come visit us at Booth 110 to learn more! #ClinicalImmunologySociety #FDAApproval #BreakThroughTherapy
-
-
We're grateful to the Immune Deficiency Foundation for their dedication to the #WHIMsyndrome community. Their efforts were vital to bringing this much-needed treatment option to those in need. Together, we're advancing innovations for people with rare diseases of the immune system and look forward to continuing our momentum in the #immunodeficiency space for years to come. We can’t thank them enough for their invaluable support and collaboration! #BreakThroughTherapy
-
-
#Savethedate for our first quarter 2024 earnings conference call & webcast on May 7. Can’t join us live? The webcast replay will be posted to the Investor Relations section of our website following the call. Find more info here: https://brnw.ch/21wJkM6
-
-
The WHIM syndrome community now has a new treatment option. #WHIMsyndrome is a rare, combined primary #immunodeficiency and chronic neutropenic disorder. Learn more here about this transformational milestone: https://brnw.ch/21wJjN4
-
-
Today marks a breakthrough for the #WHIMsyndrome community with the #FDAApproval of a therapy that targets the underlying cause of WHIM syndrome. We’d like to thank the WHIM community, those involved in our clinical trials, and our #X4tizens for making this historic milestone a reality! Press Release: https://lnkd.in/emiEbUdt
-
This #WorldPIWeek, we’d like to thank the Jeffrey Modell Foundation for their unwavering commitment to the primary immunodeficiency (PI) community! Together, let’s continue to strive towards making access to quality treatments a reality. Learn more about their mission: https://info4pi.org/hq/
-
-
#DYK that there are over 400 forms of #PrimaryImmunodeficiency? They can range widely in severity and can be classified into nine main groups. Learn more from World PI Week on how to get involved and help bring about change: https://worldpiweek.org/ #WorldPIWeek
-